SELLAS Life Sciences Group, Inc.
NASDAQ:SLSBiotechnology
+$0.31 today
- Market cap
- $3.66B
- Beta
- 2.53
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.17
Volume 35.53M
Average 7.79M
SLS Total Current Liabilities
All obligations due within one year.
SELLAS Life Sciences Group, Inc.NASDAQ: SLS
Total Current Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total current liabilities rises 56.7% from a year ago
Total current liabilities stood at $9.29M at the end of Q3 FY2026, up 56.7% from a year earlier and up 22.7% from the prior quarter. Over 3 fiscal years it compounded at -23.2% a year.
Context
- Total current liabilities amounted to 6.6% of total assets at the end of Q3 FY2026, down 4.9 pp from a year earlier.
- Total current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +56.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 7.02M USD
- Year-over-year change
- -26.2%
- 4-year CAGR
- +8.9%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.02M | -26.2% |
| FY2024 | 2024-12-31 | 9.51M | -30.8% |
| FY2023 | 2023-12-31 | 13.74M | -11.5% |
| FY2022 | 2022-12-31 | 15.52M | +211.4% |
| FY2021 | 2021-12-31 | 4.98M | — |
Total Current Liabilities vs competitors
How SLS compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +56.7% is the 6th highest of 11, against a peer median of +49.9%.
- Total current liabilities amounts to 6.6% of total assets for SLS, versus a peer median of 9.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥1.64B CNY | +41.0% | +23.1% | 41.5% |
| Jun 2026 | $1.31B USD | +2.6% | +9.4% | 16.7% | |
| Aug 2026 | $130.74M USD | +58.8% | +7.0% | 10.9% | |
| Mar 2026 | $95.94M USD | +73.0% | -3.9% | 44.0% | |
| Mar 2026 | $64.83M USD | +27.5% | +22.9% | 6.3% | |
| Mar 2026 | $41.72M USD | +110.8% | +34.7% | 34.9% | |
| Sep 2026 | $40.97M USD | +30.3% | +83.1% | 8.1% | |
| Mar 2026 | $27.25M USD | -33.2% | -9.5% | 8.3% | |
| Mar 2026 | $25M USD | +93.0% | +45.9% | 7.2% | |
| Mar 2026 | $14.19M USD | +442.4% | +59.6% | 7.1% | |
| Sep 2026 | $9.29M USD | +56.7% | -23.2% | 6.6% | |
| Peer median (excluding SLS) | — | +49.9% | +23.0% | 9.6% | |
Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21.46M | 17.13M | 2.53M | 13.89M | 71.89M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 27K | 330K | 100K | 100K | 223K |
| Total Current Assets | 23.04M | 17.76M | 3.17M | 16.33M | 75.21M |
| Property, Plant & Equipment (Net) | 723K | 874K | 858K | 925K | 963K |
| Goodwill | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | (184K) | 0 | 0 | 0 |
| Tax Assets | 152K | 184K | 0 | 0 | 0 |
| Other Non-current Assets | 594K | 399K | 275K | 466K | 257K |
| Total Non-current Assets | 3.38M | 3.19M | 3.05M | 3.31M | 3.13M |
| Total Assets | 26.43M | 20.94M | 6.22M | 19.43M | 78.35M |
| Account Payables | 2.14M | 3.36M | 5.64M | 3.5M | 2.95M |
| Short-term Debt | 198K | 0 | 0 | 0 | 544K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.65M | 5.5M | 1.54M | 1.82M | 1.77M |
| Total Current Liabilities | 4.98M | 15.52M | 13.74M | 9.51M | 7.02M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 152K | 184K | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | (184K) | 0 | 0 | 0 |
| Other Non-current Liabilities | 336K | 4K | 0 | 0 | 0 |
| Total Non-current Liabilities | 1.1M | 577K | 460K | 457K | 457K |
| Total Liabilities | 6.08M | 16.09M | 14.2M | 9.97M | 7.47M |
| Common Stock | 2K | 2K | 3K | 7K | 15K |
| Retained Earnings | (138.6M) | (179.9M) | (217.24M) | (248.13M) | (274.99M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 20.35M | 4.85M | (7.98M) | 9.47M | 70.87M |
| Total Debt | 808K | 945K | 906K | 1M | 1M |
| Net Debt | (20.65M) | (16.18M) | (1.62M) | (12.89M) | (70.89M) |
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
Intrinsic Alpha fair value
Locked
Current Price
$17.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.